Teva Receives Approval for Generic Biaxin

Teva Pharmaceutical has received final approval from the FDA for its abbreviated new drug application for clarithromycin extended-release tablets in a 500-mg dosage form.

Teva's tablets are the generic equivalent of Abbott's antibiotic Biaxin XL filmtabs. The brand product has annual sales of roughly $284 million, according to Teva.